NCT06821997: An ongoing trial by Roswell Park Cancer Institute
This trial is ongoing. It must report results 2 years, 2 months from now.
Full data
| Full entry on ClinicalTrials.gov | NCT06821997 |
|---|---|
| Title | A Phase 2 Clinical Trial of Nalirifox as Neoadjuvant Treatment for Patients With Borderline Resectable Pancreatic Ductal Adenocarcinoma (Nectar Study) |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Dec. 1, 2025 |
| Completion date | March 1, 2027 |
| Required reporting date | Feb. 29, 2028, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |